Creation of Innovative Core Technologies / Global Biopharmaceutical Supply

JCR developed the proprietary JBC platform to deliver therapies across the BBB—the world’s first to achieve clinical application in humans.
Building on this, we aim to create innovative treatments for unmet needs by advancing highly selective delivery technologies such as JBC and JUST-AAV. Through ongoing research from preclinical to clinical stages, we are working to demonstrate the true value of these platforms. We continue to invest heavily in R&D and world-class manufacturing, while proactively pursuing global collaborations and licensing opportunities—including for the technologies themselves.

Building a Global Biopharmaceutical Supply Network

Bio-based medicines demand more sophisticated manufacturing processes and stricter quality control than small-molecule drugs. We maintain integrated production and quality control across R&D and commercial production. This ensures rapid, consistent output without compromising quality. We also adopt advanced manufacturing methods such as single-use technologies and digital transformation (DX) initiatives.
To ensure a reliable supply of high-quality biologics, we conduct regular audits of raw material suppliers and maintain consistent quality systems across all sites. By establishing a quality-first culture and fostering talent with strong technical expertise, we are building a sustainable production framework.
We maintain a stable global supply chain, including for investigational drugs, by securing appropriate inventories of raw materials and products and operating with flexible, efficient production schedules.

New Formulation Plant

Rendering of the New Formulation Plant

Construction is underway on a new formulation plant adjacent to the API facility at the Kobe Science Park Center, completed in November 2022. The plant is being built with government subsidies under the Ministry of Economy, Trade and Industry’s program to strengthen vaccine production capabilities during emergencies. In normal times, the facility will be used for manufacturing biologics.